Probe: Alzheimer’s Drug Approval ‘Rife With Irregularities’
WASHINGTON (AP) — The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.”
The 18-month investigation by two House committees detailed “atypical collaboration” between FDA regulators and a company it’s supposed to oversee — Aduhelm manufacturer Biogen. The probe also cited Biogen documents saying the company intended to “make history” when it set what investigators called an “unjustifiably high” initial price of $56,000 a year for the drug.
The criticism comes as the FDA is expected to decide whether to approve another new Alzheimer’s drug in January. Thursday’s report urged the agency to “take swift action” to ensure that any future Alzheimer’s approvals aren’t met with “the same doubts about the integrity of FDA’s review.”
The FDA and Biogen issued statements Thursday defending the Aduhelm approval process.
In 2021, the FDA overruled its own independent scientific advisers when it approved Aduhelm even though research studies failed to prove it really helped patients. Biogen had halted two studies after disappointing results suggested the drug wasn’t slowing Alzheimer’s inevitable worsening — only to later contend that a new analysis of one study showed higher doses offered an incremental benefit.
The FDA argued the drug’s ability to reduce a hallmark of Alzheimer’s, a buildup of plaque in the brain, suggested it was likely to slow the disease. Backlash was immediate as three FDA advisers resigned in protest and the agency’s then-acting chief called for an internal investigation. Eventually Medicare refused to pay for the drug — even after the yearly price was dropped to $28,000 — unless patients enrolled in clinical trials to prove if it indeed slowed cognitive decline.
Thursday’s report said FDA and Biogen engaged in an unusually high volume of phone calls, meetings and emails, some of them not properly documented. In addition, the regulators and company spent months working together to prepare a briefing document for FDA’s advisers that didn’t adequately represent substantial disagreement within the FDA about how to handle Aduhelm, the report said.
The investigators recommended that FDA take steps to restore trust in the approval process that include properly documenting interactions with drugmakers. They also urged manufacturers to take into account advice from patient groups and other outside experts on fair drug pricing.
In a statement Thursday, FDA said the Aduhelm decision “was based on our scientific evaluation of the data” and that the agency’s own internal review found its interactions with Biogen were appropriate. But it said it plans to update guidance on Alzheimer’s drug development and will review the investigation’s findings.
In its own statement, Biogen said: “Alzheimer’s is a highly complex disease and we have learned from the development and launch of Aduhelm” but that it “stands by the integrity of the actions we have taken.”
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
In The News
WASHINGTON — The chief executive of Moderna Inc. defended his plan to quadruple the price of the COVID-19 vaccine during... Read More
WASHINGTON — The chief executive of Moderna Inc. defended his plan to quadruple the price of the COVID-19 vaccine during a Senate hearing Wednesday by saying his company is preparing for a sharp decline in demand. With as much as a 90% drop in customers as... Read More
NEW YORK (AP) — Nearly 200 years after Ludwig van Beethoven's death, researchers pulled DNA from strands of his hair,... Read More
NEW YORK (AP) — Nearly 200 years after Ludwig van Beethoven's death, researchers pulled DNA from strands of his hair, searching for clues about the health problems and hearing loss that plagued him. They weren't able to crack the case of the German composer's deafness or... Read More
NEW YORK (AP) — U.S. cases of a dangerous fungus tripled over just three years, and more than half of... Read More
NEW YORK (AP) — U.S. cases of a dangerous fungus tripled over just three years, and more than half of states have now reported it, according to a new study. The COVID-19 pandemic likely drove part of the increase, researchers at the Centers for Disease Control... Read More
WASHINGTON — A week after the House overwhelmingly voted to declassify any and all information related to the origin of... Read More
WASHINGTON — A week after the House overwhelmingly voted to declassify any and all information related to the origin of COVID-19, President Joe Biden signed the measure into law, saying, “I share the Congress’ goal of releasing as much information as possible” about the virus. The... Read More
BOSTON — Encouraged by positive topline results from its phase 3 trial for its new therapy for adults with schizophrenia,... Read More
BOSTON — Encouraged by positive topline results from its phase 3 trial for its new therapy for adults with schizophrenia, Karuna Therapeutics announced Monday that it is on track to submit KarXT to the Food and Drug Administration for approval by summer. If that comes to... Read More
WASHINGTON — President Joe Biden and First Lady Dr. Jill Biden are teaming up with Apple TV+’s “Ted Lasso” on... Read More
WASHINGTON — President Joe Biden and First Lady Dr. Jill Biden are teaming up with Apple TV+’s “Ted Lasso” on Monday to highlight “the importance of addressing your mental health to promote overall well-being.” The first couple hosted actor Jason Sudeikis and other members of the... Read More